Patents by Inventor Yaohuang Ke
Yaohuang Ke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220348674Abstract: The present disclosure provides anti-CD40 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.Type: ApplicationFiled: April 30, 2021Publication date: November 3, 2022Inventors: Chan GAO, Mu-En LIN, Qiu YU, Yaohuang KE
-
Publication number: 20220089758Abstract: The present disclosure provides anti-CD40 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.Type: ApplicationFiled: January 22, 2020Publication date: March 24, 2022Inventors: Mu-En LIN, Qiu YU, Hui LI, Yaohuang KE
-
Patent number: 10377814Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: GrantFiled: April 1, 2016Date of Patent: August 13, 2019Assignee: EPITOMICS, INC.Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
-
Patent number: 9951136Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.Type: GrantFiled: May 2, 2014Date of Patent: April 24, 2018Assignee: APEXIGEN, INC.Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
-
Patent number: 9441042Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.Type: GrantFiled: November 1, 2012Date of Patent: September 13, 2016Assignee: Apexigen, Inc.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20160207982Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: ApplicationFiled: April 1, 2016Publication date: July 21, 2016Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qian Qi, Harry C. Au
-
Patent number: 9365644Abstract: An antibody that binds TNF ? and neutralizes its activity is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1, and b) a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID No. 2.Type: GrantFiled: April 17, 2009Date of Patent: June 14, 2016Assignee: EPITOMICS, INC.Inventors: Yaohuang Ke, Guo-Liang Yu
-
Patent number: 9328333Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: GrantFiled: January 2, 2013Date of Patent: May 3, 2016Assignee: EPITOMICS, Inc.Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
-
Patent number: 9085621Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.Type: GrantFiled: September 9, 2011Date of Patent: July 21, 2015Assignee: Apexigen, Inc.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
-
Patent number: 9079942Abstract: A method of obtaining nucleic acid encoding a plurality of antibodies is provided. In certain embodiments, the method comprises obtaining from an immunized animal nucleic acid encoding the amino acid sequence of the heavy and light chains of a second antibody that binds to the antigen as a first antibody and differs in amino acid sequence to the first antibody, wherein the obtaining is done by amplification using: i. a first primer pair that includes oligonucleotides are complementary to CDR-encoding regions first antibody.Type: GrantFiled: January 28, 2010Date of Patent: July 14, 2015Assignee: EPITOMICS, INC.Inventors: Yaohuang Ke, Guo-Liang Yu
-
Patent number: 9057728Abstract: In certain embodiments, the method may comprises: a) contacting a population of permeabilized, cross-linked antibody-producing cells with a labeled antigen to produce a labeled sample in which cells that produce an antibody that specifically binds to said antigen are intracellularly labeled; b) using FACS to isolate cells that are intracellularly labeled, thereby producing labeled cells; c) uncrosslinking said labeled cells to produce uncrosslinked cells; and d) amplifying heavy and light chain-encoding nucleic acid from individual uncrosslinked cells, thereby obtaining nucleic acid that encodes the variable domain of antibody that specifically binds to said antigen.Type: GrantFiled: July 10, 2012Date of Patent: June 16, 2015Assignee: Epitomics, Inc.Inventors: Yaohuang Ke, Guo-Liang Yu, Karin Vroom
-
Patent number: 8986692Abstract: The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.Type: GrantFiled: August 27, 2010Date of Patent: March 24, 2015Assignees: Jiangsu Simcere Pharmaceutical R & D Co., Ltd., Apexigen Inc.Inventors: Pierre Li, Yaohuang Ke, Yongke Zhang, Weimin Zhu, Guoliang Yu, Fanxin Ma, Xin Fan
-
Publication number: 20140377282Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.Type: ApplicationFiled: November 1, 2012Publication date: December 25, 2014Applicant: APEXIGEN, INC.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20140349393Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: ApplicationFiled: May 20, 2014Publication date: November 27, 2014Applicant: Epitomics, Inc. (c/o Abcam plc)Inventors: ROBERT PYTELA, WEIMIN ZHU, YAOHUANG KE, QI QIAN, HARRY C. AU
-
Publication number: 20140322239Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.Type: ApplicationFiled: May 2, 2014Publication date: October 30, 2014Applicant: APEXIGEN, INC.Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
-
Patent number: 8753634Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.Type: GrantFiled: February 28, 2012Date of Patent: June 17, 2014Assignee: Apexigen, Inc.Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
-
Publication number: 20140004566Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: ApplicationFiled: January 2, 2013Publication date: January 2, 2014Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qian Qi, Harry C. Au
-
Publication number: 20130330355Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.Type: ApplicationFiled: September 9, 2011Publication date: December 12, 2013Applicant: APEXIGEN, INC.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
-
Patent number: 8367408Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: GrantFiled: October 17, 2011Date of Patent: February 5, 2013Assignee: EPITOMICS, Inc.Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
-
Publication number: 20130017555Abstract: In certain embodiments, the method may comprises: a) contacting a population of permeabilized, cross-linked antibody-producing cells with a labeled antigen to produce a labeled sample in which cells that produce an antibody that specifically binds to said antigen are intracellularly labeled; b) using FACS to isolate cells that are intracellularly labeled, thereby producing labeled cells; c) uncrosslinking said labeled cells to produce uncrosslinked cells; and d) amplifying heavy and light chain-encoding nucleic acid from individual uncrosslinked cells, thereby obtaining nucleic acid that encodes the variable domain of antibody that specifically binds to said antigen.Type: ApplicationFiled: July 10, 2012Publication date: January 17, 2013Inventors: Yaohuang Ke, Guo-Liang Yu, Karin Vroom